ChemGenex on a roll
Tuesday, 01 July, 2008
ChemGenex [ASX: CXS] has submitted the non-clinical section of its New Drug Application [NDA] to the US FDA for omacetaxine, the company's chronic myeloid leukaemia treatment.
The non-clinical section is the first of three in the company's rolling submission: the next steps are the chemistry and manufacturing controls segment and the clinical section.
ChemGenex expects that both remaining submissions will be complete by mid-2009.
The FDA has already granted fast-track designation to the drug, omacetaxine mepesuccinate, for treatment of patients who have failed prior treatment with Novartis' imatinib mesylate, or Glivec.
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
Space conditions can lead to periodontitis, scientists say
Living in zero gravity can lead to periodontitis — a serious condition where the gums...
Personalised brain stimulation helps treat those with depression
By tailoring transcranial magnetic stimulation to each person's unique brain structure,...
